Mitragynine vs. 7 Hydroxymitragynine: What's the Difference?

If you have researched kratom, you have probably encountered two names repeatedly: mitragynine and 7 hydroxymitragynine, often shortened to 7 OH.

Both are naturally occurring alkaloids associated with Mitragyna speciosa, the tree commonly known as kratom. However, they are not the same compound. They differ in chemical structure, abundance in the plant, pharmacological activity, and the way researchers understand their role in kratom's effects.

The distinction also matters because concentrated products containing elevated levels of 7 OH are increasingly receiving regulatory and public health attention. The US Food and Drug Administration has specifically warned consumers about products containing added or enhanced 7 OH.

This guide explains the difference between mitragynine and 7 hydroxymitragynine without treating preliminary research as established medical fact.

Mitragynine and 7 hydroxymitragynine are different alkaloids associated with kratom. Mitragynine is the most abundant alkaloid in typical kratom leaf, while 7 hydroxymitragynine occurs naturally at much lower levels and has substantially stronger activity at the mu opioid receptor in laboratory research. Mitragynine can also be metabolized into 7 hydroxymitragynine, making their relationship more complex than a simple comparison.

What Is Mitragynine?

Mitragynine is an indole alkaloid found in the leaves of Mitragyna speciosa, commonly called kratom. It is generally described as the predominant alkaloid in kratom and has become one of the most extensively studied compounds in the plant.

Kratom leaves contain many alkaloids, but research has focused heavily on mitragynine and 7 hydroxymitragynine because of their interactions with opioid receptors and other biological systems.

One important point is that mitragynine is not simply another name for kratom. Kratom is the plant material, while mitragynine is one chemical constituent within that plant.

The concentration of mitragynine can also vary. Research has reported differences associated with factors such as plant material, geographic origin, age, growing conditions, and other variables.

This means that two kratom products can both be described as kratom while having different alkaloid profiles.

What Does Mitragynine Do?

Laboratory research shows that mitragynine interacts with several receptor systems. Its best studied activity involves the mu opioid receptor, where it behaves differently from conventional opioid drugs and has been described as a partial agonist.

Research also indicates that mitragynine interacts with other biological targets, which may help explain why kratom pharmacology cannot be reduced to a single receptor or mechanism.

Importantly, laboratory findings should not automatically be interpreted as proof that kratom or mitragynine produces a particular medical outcome in humans.

The current evidence base includes substantial preclinical research, but human research remains more limited than research involving many established pharmaceutical compounds.

What Is 7 Hydroxymitragynine?

7 hydroxymitragynine is another alkaloid associated with Mitragyna speciosa. It is often called 7 OH for short.

Unlike mitragynine, 7 OH is naturally present in kratom at much lower concentrations. Research has nevertheless attracted significant attention to it because its activity at the mu opioid receptor is considerably stronger than that of mitragynine in laboratory studies.

The relationship between the two compounds becomes even more interesting because research has found that mitragynine can be metabolized into 7 hydroxymitragynine.

A 2019 study reported that mitragynine was converted into 7 hydroxymitragynine in both mouse and human liver preparations, with CYP3A enzymes involved in the process. The researchers also found evidence of this conversion in mice.

That finding is one reason researchers do not view mitragynine and 7 OH as completely independent substances.

Mitragynine vs. 7 Hydroxymitragynine: The Main Differences

The easiest way to understand the distinction is to compare their major characteristics.

The most important distinction is this:

Mitragynine is abundant but comparatively less potent at the mu opioid receptor, while 7 hydroxymitragynine is much less abundant but substantially more potent at that receptor.

That difference between quantity and potency is critical.

A compound can be present in a smaller amount while still having a significant pharmacological effect because potency describes how strongly a compound acts at a particular biological target.

Why Is 7 OH More Potent Than Mitragynine?

The difference is largely related to their chemical structures and how they interact with opioid receptors.

Mitragynine and 7 hydroxymitragynine have related structures, but the addition of a hydroxyl group at the seventh position changes the molecule's pharmacological properties.

Research comparing the two compounds has consistently found stronger mu opioid receptor activity for 7 OH. A recent review of kratom pharmacology describes mitragynine as a relatively weak partial agonist at the mu opioid receptor and 7 OH as a considerably more potent agonist.

Some studies have reported substantially higher receptor affinity for 7 OH than mitragynine. However, numbers reported across studies should be interpreted carefully because experimental methods, receptor preparations, and testing conditions can differ.

This is an important distinction for readers:

Higher potency in a laboratory assay does not automatically mean a predictable effect in a person.

Pharmacological activity depends on factors including absorption, metabolism, distribution, concentration, route of administration, other compounds, and individual biology.

Is 7 Hydroxymitragynine Naturally Found in Kratom?

Yes. 7 hydroxymitragynine occurs naturally in kratom, but typically at much lower concentrations than mitragynine.

This point is especially important when discussing modern 7 OH products.

The FDA has distinguished between the naturally occurring trace amounts of 7 OH in kratom and products that contain 7 OH as an added ingredient or at enhanced concentrations. The agency has warned consumers about concentrated 7 OH products and says such products have not been proven safe or effective for any medical use.

In other words, the phrase "contains 7 OH" does not tell you everything about a product.

There is a meaningful difference between:

• naturally occurring alkaloids in kratom leaf
• concentrated kratom extracts
• products specifically formulated around elevated 7 OH
• synthetic or chemically modified compounds related to 7 OH

Those categories should not be treated as interchangeable.

Why Concentration Matters

The concentration of an alkaloid can change the chemical profile of a product.

A traditional kratom leaf product contains a complex mixture of alkaloids rather than one isolated compound. By contrast, a concentrated product can have a substantially different alkaloid distribution.

This is why consumers should examine product labeling and testing information rather than assuming that every product marketed under the kratom name has the same composition.

How Does the Body Process Mitragynine?

One of the most important discoveries in mitragynine research is that the body can metabolize it into other compounds, including 7 hydroxymitragynine.

The 2019 research discussed earlier found evidence that mitragynine can undergo metabolism through CYP3A enzymes, producing 7 hydroxymitragynine.

This matters because researchers are still determining how much of the biological activity associated with mitragynine comes from mitragynine itself and how much may involve metabolites.

A later clinical pharmacology review described 7 hydroxymitragynine as an oxidative metabolite of mitragynine and highlighted the need for additional research into kratom's pharmacology and safety.

Why Metabolism Makes the Comparison More Complicated

Imagine comparing two ingredients based only on what is present in the original product.

That approach can miss an important part of the picture if one compound is transformed into another after consumption.

For mitragynine, researchers have evidence that metabolism can produce 7 hydroxymitragynine. However, the amount formed and its significance in humans are still areas of investigation.

Individual differences in metabolism may also affect exposure to these compounds.

This is one reason it is inappropriate to assume that a particular labeled alkaloid concentration guarantees a particular experience or outcome.

Does More Mitragynine Mean More 7 OH?

Not necessarily.

The amount of mitragynine in a product does not provide a simple formula for predicting how much 7 hydroxymitragynine will ultimately be produced in an individual.

Several factors complicate the relationship:

1. Product composition: Kratom products contain different combinations and concentrations of alkaloids.
2. Metabolism: The body processes compounds through enzymatic pathways.
3. Individual biology: Metabolic activity varies between people.
4. Product format: Powder, capsules, extracts, and other formats may have different chemical profiles.
5. Testing methods: Different laboratories and analytical methods can produce different measurements.
6. Dose and exposure: The amount consumed influences systemic exposure.
7. Other substances: Concurrent substances may affect metabolism and pharmacological effects.

Research involving human volunteers has also investigated interactions affecting the pharmacokinetics of mitragynine and 7 OH, illustrating why metabolism and drug interactions deserve careful attention.

For consumers, the practical lesson is simple:

Do not use a mitragynine number as a precise prediction of 7 OH exposure.

Why Product Testing Matters

Understanding mitragynine and 7 hydroxymitragynine is not only a chemistry question. It is also a product transparency question.

If a company provides meaningful laboratory testing information, consumers may have a better opportunity to understand what is actually present in a product.

Depending on the product and testing program, laboratory analysis may provide information about alkaloid content and help identify certain contaminants or quality issues.

However, consumers should distinguish between a company saying that a product is "tested" and actually providing useful testing information.

What Should a Consumer Look For?

When evaluating a kratom product, consider whether the company provides:

• Clear product labeling
• Specific ingredient information
• Accessible laboratory testing information
• Relevant Certificates of Analysis when available
• Product identification that matches the testing documentation
• Transparent contact information
• Clear purchasing and customer support information
• Information that does not rely on exaggerated health promises

A Certificate of Analysis can be useful, but it should also be interpreted carefully. A COA is only meaningful when the document corresponds to the product being purchased and provides enough information to understand what was tested.

Kratom Leaf vs. Concentrated 7 OH Products

The growing discussion around 7 OH has made it especially important to distinguish traditional kratom products from products specifically formulated with elevated concentrations of 7 OH.

Traditional kratom leaf naturally contains a mixture of alkaloids. Mitragynine generally represents the dominant alkaloid, while 7 hydroxymitragynine is present in much smaller quantities.

Concentrated 7 OH products are different because they can deliver substantially higher amounts of 7 OH than would ordinarily be expected from unprocessed plant material.

The FDA has specifically warned consumers about products containing enhanced or added 7 OH, including products marketed as tablets, gummies, drink mixes, and shots.

The agency's current public health messaging is therefore important when evaluating products that emphasize 7 OH concentration.

As of 2026, US regulatory activity concerning concentrated 7 OH products has also continued to develop. The FDA reported that on July 1, 2026, the DEA began a temporary scheduling process involving 7 OH above a proposed threshold, along with certain synthetic 7 OH derivatives, while HHS opened a related public comment process.

Regulatory status can change, and laws can differ by jurisdiction. Consumers should verify the rules that apply where they live rather than relying on an older article or product listing.

What the Research Can and Cannot Tell Us

A large amount of scientific literature exists on kratom alkaloids, but it is important to understand the limits of that evidence.

What Research Supports

Current research supports several broad conclusions:

• Mitragynine is a major alkaloid in kratom.
• 7 hydroxymitragynine occurs naturally in kratom at much lower levels.
• Both compounds interact with opioid receptor systems.
• 7 hydroxymitragynine has substantially greater mu opioid receptor activity than mitragynine in laboratory research.
• Mitragynine can be metabolized into 7 hydroxymitragynine.
• Kratom pharmacology involves more than one biological pathway.
• Safety and dependence questions remain active areas of research.

What Research Does Not Establish

Research does not justify claims that kratom or either alkaloid:

• Treats a specific disease
• Cures a medical condition
• Is universally safe
• Produces a guaranteed effect
• Has the same effects for every person
• Is equivalent to a pharmaceutical medication
• Can be used without considering potential interactions or adverse effects

The FDA has warned about serious adverse events associated with kratom, including liver toxicity, seizures, and substance use disorder, and notes that deaths involving kratom have generally involved other substances as well, making causation difficult to determine in individual cases.

This is why responsible kratom education should communicate both what scientists know and what remains uncertain.

What Should Consumers Look for in a Kratom Product?

If your goal is to understand a kratom product rather than simply choose one based on a marketing claim, start with the product information.

1. Understand the Product Format

Kratom can be sold in formats such as:

• Powder
• Capsules
• Extracts
• Other formulated products

The format can affect how the product is presented and its alkaloid concentration.

2. Look at the Label

A clear label should make it possible to identify what you are purchasing.

Avoid relying solely on statements such as "strong," "premium," or "powerful." These descriptions do not provide the same information as measurable product specifications.

3. Consider Alkaloid Information

If a company provides laboratory verified alkaloid information, examine it in context.

Remember that mitragynine concentration does not directly tell you the amount of 7 hydroxymitragynine that might be generated through metabolism.

4. Look for Testing Transparency

If laboratory testing is available, determine whether the documentation identifies the product and provides relevant results.

5. Avoid Unsupported Medical Claims

A trustworthy educational resource should distinguish scientific research from marketing language.

Be cautious of product descriptions that promise to diagnose, prevent, treat, or cure medical conditions.

6. Check Current Local Rules

Kratom regulations can differ between countries, states, cities, and other jurisdictions.

A product being available online does not necessarily mean its sale or possession is lawful everywhere.

How Does 7 OH Compare With Mitragynine in Simple Terms?

Here is the simplest way to remember the distinction:

Mitragynine is the major alkaloid. 7 hydroxymitragynine is a much less abundant alkaloid with substantially greater activity at the mu opioid receptor.

You can think of the relationship as a combination of quantity, potency, and metabolism.

Mitragynine is present in much larger amounts in typical kratom leaf. 7 OH is present in much smaller amounts, but laboratory research shows that it interacts more strongly with the mu opioid receptor.

At the same time, mitragynine can be metabolized into 7 OH, which means the two compounds are biologically connected.

That is why looking at either compound in isolation provides an incomplete picture of kratom pharmacology.

Why This Difference Matters When Reading Kratom Labels

Suppose two products list different alkaloid profiles.

It would be tempting to look only at the mitragynine percentage and assume that the product with more mitragynine is automatically "stronger."

That conclusion would be too simplistic.

A product's overall chemical profile, including its alkaloid composition and concentration, matters. So do extraction methods, testing procedures, product format, and the individual's metabolism.

For consumers, a better approach is to ask:

• What exactly is in the product?
• Is the product's alkaloid profile clearly described?
• Is laboratory testing available?
• Does the testing correspond to the product?
• Is the product a conventional kratom preparation or a concentrated formulation?
• Does the company make responsible claims?
• Are there relevant regulatory restrictions where I live?

These questions lead to a more informed purchasing decision than focusing on one number.

If you are comparing formats, review PurKratom's available kratom powder, capsule, and extract options alongside the product information provided for each one.

Frequently Asked Questions (FAQs)

1. What is the difference between mitragynine and 7 hydroxymitragynine?

Mitragynine and 7 hydroxymitragynine are different alkaloids associated with kratom. Mitragynine is generally much more abundant in kratom leaf, while 7 OH occurs naturally at lower levels and has substantially stronger activity at the mu opioid receptor in laboratory studies.

2. Is 7 hydroxymitragynine naturally found in kratom?

Yes. 7 hydroxymitragynine occurs naturally in Mitragyna speciosa, but normally at much lower concentrations than mitragynine. The FDA has distinguished these naturally occurring amounts from products containing added or enhanced 7 OH.

3. Is 7 OH stronger than mitragynine?

In laboratory pharmacological research, 7 OH has substantially greater activity and affinity at the mu opioid receptor than mitragynine. However, laboratory potency should not be interpreted as a guaranteed or predictable effect in humans.

4. Does mitragynine turn into 7 hydroxymitragynine?

Research indicates that mitragynine can be metabolized into 7 hydroxymitragynine. Studies have demonstrated this conversion in liver preparations and animal models. The significance and extent of this process in individual humans remain subjects of research.

5. Does more mitragynine mean more 7 OH?

No. Mitragynine concentration does not provide a simple way to predict an individual's 7 OH exposure. Metabolism, product composition, dose, biological differences, and other factors can influence the relationship.

6. Why is 7 OH receiving so much regulatory attention?

Concentrated 7 OH products have raised public health concerns because 7 OH has substantially stronger opioid receptor activity than mitragynine. The FDA has warned consumers against products containing added or enhanced 7 OH and has continued to monitor the issue.

7. Are mitragynine and 7 OH opioids?

Both compounds interact with opioid receptors, particularly the mu opioid receptor. However, describing their pharmacology simply as identical to conventional pharmaceutical opioids would be misleading because their receptor activity and broader pharmacology differ. Research continues to investigate their mechanisms and risks.

8. Is kratom safe because it is a plant?

Being plant derived does not automatically establish safety. Kratom contains pharmacologically active compounds, and public health agencies have raised concerns about adverse effects, interactions, dependence, and product quality.

Mitragynine and 7 hydroxymitragynine are closely related but distinct alkaloids found in kratom.

The biggest difference is that mitragynine is generally the predominant alkaloid in kratom leaf, while 7 hydroxymitragynine occurs at much lower natural concentrations but demonstrates substantially greater activity at the mu opioid receptor in laboratory research.

Their relationship is also more complicated than their concentrations suggest. Research indicates that the body can metabolize mitragynine into 7 hydroxymitragynine, meaning metabolism may contribute to the overall pharmacological profile associated with mitragynine.

For consumers, the key lesson is not to judge a kratom product by a single alkaloid number or marketing phrase. Product format, alkaloid profile, laboratory testing, labeling, regulatory status, and responsible company practices all deserve consideration.

The distinction becomes particularly important when comparing conventional kratom products with concentrated 7 OH products. Current FDA warnings specifically emphasize concerns about products containing added or enhanced 7 OH.

Continue your research by reviewing PurKratom’s relevant kratom collection, product information, and available testing documentation before evaluating a kratom product.

Disclaimer: This content is for educational and informational purposes only and is not intended to provide medical advice, diagnose, treat, cure, or prevent any disease or health condition. Kratom research is still developing, and individual responses may vary. Consult a qualified healthcare professional before using kratom, especially if you take medications, have a medical condition, are pregnant or breastfeeding, or have concerns about potential interactions. Laws and regulations regarding kratom vary by location and may change, so verify current local requirements before purchasing or using kratom.